Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target

References

• Trends Progress Report C. – 2011/2012 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, August 2012. Available from: http://progressreport.cancer.gov
   Google Scholar
• National Cancer Institute: PDQ® Non-Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified <05/30/2013>. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional. Accessed 06/18/2013.
   Google Scholar
• Shaw EG, Brindle JS, Creagan ET, Foote RL, Trastek VF, Buskirk SJ. Locally recurrent non-small-cell lung cancer after complete surgical resection. Mayo Clin Proc 1992; 67:1129 - 33; http://dx.doi.org/10.1016/S0025-6196(12)61141-0; PMID: 1335100
   PubMed Web of Science ®Google Scholar
• Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D’Amico TA, Boyd JA. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009; 115:5218 - 27; http://dx.doi.org/10.1002/cncr.24625; PMID: 19672942
   PubMed Web of Science ®Google Scholar
• Thomas P, Rubinstein L, Lung Cancer Study Group. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Ann Thorac Surg 1990; 49:242 - 6, discussion 246-7; http://dx.doi.org/10.1016/0003-4975(90)90145-V; PMID: 2154958
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al, ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687 - 97; http://dx.doi.org/10.1016/S0140-6736(10)61121-X; PMID: 20728210
   PubMed Web of Science ®Google Scholar
• Gorringe KL, Boussioutas A, Bowtell DD, Melbourne Gastric Cancer Group, Peter Mac Micro Array Facility. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2005; 42:247 - 59; http://dx.doi.org/10.1002/gcc.20136; PMID: 15611932
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Stuart D, Sellers WR. Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol 2009; 21:304 - 10; http://dx.doi.org/10.1016/j.ceb.2009.02.001; PMID: 19328671
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?. Trends Mol Med 2004; 10:481 - 6; http://dx.doi.org/10.1016/j.molmed.2004.08.008; PMID: 15464447
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561 - 6; http://dx.doi.org/10.1038/nature05945; PMID: 17625570
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153 - 8; http://dx.doi.org/10.1038/nature05610; PMID: 17344846
   PubMed Web of Science ®Google Scholar
• Buffart TE, Louw M, van Grieken NC, Tijssen M, Carvalho B, Ylstra B, Grabsch H, Mulder CJ, van de Velde CJ, van der Merwe SW, et al. Gastric cancers of Western European and African patients show different patterns of genomic instability. BMC Med Genomics 2011; 4:7; http://dx.doi.org/10.1186/1755-8794-4-7; PMID: 21226972
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:1021 - 7; http://dx.doi.org/10.1158/1055-9965.EPI-10-1080; PMID: 21393565
   PubMed Web of Science ®Google Scholar
• Longin S, Zwaenepoel K, Louis JV, Dilworth S, Goris J, Janssens V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. J Biol Chem 2007; 282:26971 - 80; http://dx.doi.org/10.1074/jbc.M704059200; PMID: 17635907
   PubMed Web of Science ®Google Scholar
• Ogris E, Du X, Nelson KC, Mak EK, Yu XX, Lane WS, Pallas DC. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem 1999; 274:14382 - 91; http://dx.doi.org/10.1074/jbc.274.20.14382; PMID: 10318862
   PubMed Web of Science ®Google Scholar
• Yu XX, Du X, Moreno CS, Green RE, Ogris E, Feng Q, Chou L, McQuoid MJ, Pallas DC. Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Mol Biol Cell 2001; 12:185 - 99; http://dx.doi.org/10.1091/mbc.12.1.185; PMID: 11160832
   PubMed Web of Science ®Google Scholar
• Turowski P, Myles T, Hemmings BA, Fernandez A, Lamb NJ. Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. Mol Biol Cell 1999; 10:1997 - 2015; http://dx.doi.org/10.1091/mbc.10.6.1997; PMID: 10359611
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795:1 - 15; PMID: 18588945
   PubMed Web of Science ®Google Scholar
• Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, Raheem O, Ketola K, Lin S, Kast J, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 2009; 69:2870 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-2760; PMID: 19293187
   PubMed Web of Science ®Google Scholar
• Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011; 11:38 - 46; http://dx.doi.org/10.2174/187152011794941172; PMID: 21288198
   PubMed Web of Science ®Google Scholar
• Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24:7746 - 55; http://dx.doi.org/10.1038/sj.onc.1209038; PMID: 16299534
   PubMed Web of Science ®Google Scholar
• Zhou J, Pham HT, Walter G. The formation and activity of PP2A holoenzymes do not depend on the isoform of the catalytic subunit. J Biol Chem 2003; 278:8617 - 22; http://dx.doi.org/10.1074/jbc.M211181200; PMID: 12506124
   PubMed Web of Science ®Google Scholar
• Li X, Virshup DM. Two conserved domains in regulatory B subunits mediate binding to the A subunit of protein phosphatase 2A. Eur J Biochem 2002; 269:546 - 52; http://dx.doi.org/10.1046/j.0014-2956.2001.02680.x; PMID: 11856313
   PubMedGoogle Scholar
• Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011:329098; http://dx.doi.org/10.4061/2011/329098; PMID: 21904669
   PubMedGoogle Scholar
• McCaddon A, Hudson PR. Methylation and phosphorylation: a tangled relationship?. Clin Chem 2007; 53:999 - 1000; http://dx.doi.org/10.1373/clinchem.2007.086579; PMID: 17517583
   PubMed Web of Science ®Google Scholar
• Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992; 257:1261 - 4; http://dx.doi.org/10.1126/science.1325671; PMID: 1325671
   PubMed Web of Science ®Google Scholar
• Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 2005; 65:8183 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-05-1103; PMID: 16166293
   PubMed Web of Science ®Google Scholar
• Jackson JB, Pallas DC. Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner. Neoplasia 2012; 14:585 - 99; PMID: 22904676
   PubMed Web of Science ®Google Scholar
• Ortega-Gutiérrez S, Leung D, Ficarro S, Peters EC, Cravatt BF. Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PLoS One 2008; 3:e2486; http://dx.doi.org/10.1371/journal.pone.0002486; PMID: 18596935
   PubMedGoogle Scholar
• Xing Y, Li Z, Chen Y, Stock JB, Jeffrey PD, Shi Y. Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 2008; 133:154 - 63; http://dx.doi.org/10.1016/j.cell.2008.02.041; PMID: 18394995
   PubMed Web of Science ®Google Scholar
• Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schürer SC, et al. Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci U S A 2011; 108:6811 - 6; http://dx.doi.org/10.1073/pnas.1015248108; PMID: 21398589
   PubMed Web of Science ®Google Scholar
• Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012; 136:691 - 7; http://dx.doi.org/10.5858/arpa.2011-0168-RS; PMID: 22646280
   PubMed Web of Science ®Google Scholar
• Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol 2013; 5:143 - 51; http://dx.doi.org/10.1177/1758834012469429; PMID: 23450234
   PubMedGoogle Scholar
• Dropulić B. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 2011; 22:649 - 57; http://dx.doi.org/10.1089/hum.2011.058; PMID: 21486177
   PubMed Web of Science ®Google Scholar